ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

CSCX Cardiac Science Corp (MM)

2.32
0.00 (0.00%)
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Cardiac Science Corp (MM) NASDAQ:CSCX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 2.32 0 01:00:00

- Additional Proxy Soliciting Materials (definitive) (DEFA14A)

29/10/2010 9:50pm

Edgar (US Regulatory)


 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
October 29, 2010
Date of Report (Date of earliest event reported)
CARDIAC SCIENCE CORPORATION
 
(Exact Name of Registrant as Specified in Charter)
         
Delaware   000-51512   94-3300396
         
(State or Other Jurisdiction of Incorporation)   (Commission File No.)   (IRS Employer Identification No.)
     
3303 Monte Villa Parkway, Bothell, Washington   98021
 
(Address of principal executive offices)   (Zip Code)
(425) 402-2000
 
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
  o   Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
  þ   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
  o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
  o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 


 

Item 1.01 Entry into a Material Definitive Agreement.
On October 29, 2010, Cardiac Science Corporation (the “Company”) entered into Amendment No. 1 to the Agreement and Plan of Merger, dated as of October 29, 2010, with Opto Circuits (India) Ltd. and Jolt Acquisition Company (the “Amendment”). The Amendment contains typographical revisions and other clerical changes. A copy of the Amendment is attached as Exhibit 2.1 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(d)   Exhibits.
     
Exhibit No.   Description
2.1
  Amendment No. 1 to Agreement and Plan of Merger, dated as of October 29, 2010, by and among Cardiac Science Corporation, Opto Circuits (India) Ltd. and Jolt Acquisition Company.

 


 

SIGNATURES
     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
  CARDIAC SCIENCE CORPORATION
 
 
Dated: October 29, 2010  By:   /s/ MICHAEL K. MATYSIK    
    Name:   Michael K. Matysik   
    Title:   Senior Vice President
and Chief Financial Officer 
 

 


 

         
EXHIBIT INDEX
     
Exhibit No.   Description
2.1
  Amendment No. 1 to Agreement and Plan of Merger, dated as of October 29, 2010, by and among Cardiac Science Corporation, Opto Circuits India Ltd. and Jolt Acquisition Company.*

 

1 Year Cardiac Science Corp (MM) Chart

1 Year Cardiac Science Corp (MM) Chart

1 Month Cardiac Science Corp (MM) Chart

1 Month Cardiac Science Corp (MM) Chart